Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Duke Energy Corp (DUK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Duke Energy Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while Duke Energy Corp trades at $127.67 (market cap $99.96B). The key difference: Duke Energy Corp is far larger — about 22.3× ACADIA Pharmaceuticals Inc.'s market cap, and Duke Energy Corp pays a 3.32% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DUK | |
|---|---|---|
Market Cap | $4.49B | $99.96B |
Sector | Health | Utilities |
52-Week High | $28.06 | $133.46 |
52-Week Low | $20.06 | $113.99 |
Enterprise Value | $3.69B | $190.00B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Duke Energy (DUK) trades at $128.22, down 1.06% on the day, with a bullish technical signal supported by moving averages. The company shows steady revenue growth, reaching $32.24B in 2025, and has beaten earnings estimates for the last three quarters. A $1.07 dividend is scheduled for June 2026. Analyst consensus is a Buy with a $137.67 price target, though the stock faces headwinds from high debt levels and regulatory pressures.
DUK presents a stable investment with consistent earnings and a solid dividend, but investors should weigh the upside from infrastructure investments against rising debt and regulatory risks. The stock's current valuation is reasonable, with potential for moderate growth if execution on its $103B capital plan remains on track.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
